Business Law
Sep. 17, 2026
Lilly says side effects, not competing drug, doomed Nektar treatment
Eli Lilly opened its defense against Nektar Therapeutics' contract claims, telling jurors it abandoned the autoimmune drug Rezpeg because of injection-site reactions and disappointing efficacy data, not to protect a competing eczema treatment.
Eli Lilly & Co. opened its defense Wednesday against claims that it shelved a promising autoimmune drug to avoid competing with another treatment, telling jurors that side effects and disappointing efficacy data -- not corporate self-interest -- drove the decision.
Lilly's first witness, Chief Scientific and Product Officer Dan Skovronsky, described the company's early enthusiasm for Rezpeg and growing concerns about injection-site reactions that eventually contributed...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In